

DRUG DRUG INTERACTIONS – WHEN IS COBICISTAT NOT RITONAVIR, WHEN IS TAF NOT TDF?

Duncan A¹

¹ Pharmacy Department, the Alfred Hospital, Melbourne

Drug interactions are different for any novel antiretroviral agent.

For cobicistat and tenofovir AF, drug interactions are not always the same as their existing counterparts. When considering using these agents, it is important to think of them as new entities and thus their potential for drug interactions as different.

Tenofovir AF is significantly affected by p-glycoprotein efflux and consequently must not be given with inducers of p-glycoprotein; this is less relevant with tenofovir DF. Cobicistat and ritonavir share some inhibitory cytochrome P450 interactions, but ritonavir has a much broader effect on liver enzymes; they cannot be readily interchanged without considering a patient's other medication.

When switching between older and newer agents, always consider the current antiretroviral regimen's effect on the patient's concomitant medication (or vice versa), and how it may be different should a change in regimen occur.

Disclosure of Interest Statement:

Alison has participated in advisory boards for ViiV and Gilead